Debbie Rigby rounds up the latest in research news
The American Heart Association has released an update on the role of omega-3 fatty acids in the management of hypertriglyceridaemia. It concludes that prescription n-3 FAs (EPA+DHA or EPA-only) at a dose of 4 g/d (>3 g/d total EPA+DHA) are an effective and safe option for reducing triglycerides as monotherapy or as an adjunct to other lipid-lowering agents. The REDUCE-IT (Reduction of Cardiovascular Events With EPA Intervention Trial), a randomized placebo-controlled trial of EPA-only in high-risk patients treated with a statin shopwed a 25% reduction in major adverse cardiovascular events.
A systematic review of 35 studies explored the range of dosing of cannabidiol in a variety of medical conditions. Twenty‐three studies reported a significant improvement in primary outcomes (e.g. psychotic symptoms, anxiety, seizures), with doses ranging between <1 and 50 mg/kg/day. Epilepsy was the most frequently studied medical condition, reducing seizure frequency or severity in average doses of 15mg/kg/day.
Br J Clin Pharmacol. 2019;85:1888–1900.
PBS claims data shows use of anticholinergic medicines is common among patients initiating dementia medicines (donepezil, rivastigmine, galantamine or memantine). Among patients exposed to anticholinergic medicines, 46% had the same medicine dispensed before and after initiating dementia medicines. Antipsychotics use increased by 10.1% after initiating dementia medicines.
Br J Clin Pharmacol. 2019;85:1957–1963.
A systematic review and meta‐analysis of 52 studies (30,376 residents) shows pharmacists contribute substantially to patient care in nursing homes, ensuring quality use of medication, resulting in reduced fall rates. Mixed results were noted on the impact of pharmacists’ services on mortality, hospitalization and admission rates among residents.
Br J Clin Pharmacol, first published 29 August 2019.